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Abstract
Background: Erythropoiesis stimulating agents (ESAs) are widely used to treat anaemia but concerns exist about their
potential to promote pathological angiogenesis in some clinical scenarios. In the current study we have assessed the
angiogenic potential of three ESAs; epoetin delta, darbepoetin alfa and epoetin beta using in vitro and in vivo models.
Methodology/Principal Findings: The epoetins induced angiogenesis in human microvascular endothelial cells at high
doses, although darbepoetin alfa was pro-angiogenic at low-doses (1–20 IU/ml). ESA-induced angiogenesis was VEGF-
mediated. In a mouse model of ischaemia-induced retinopathy, all ESAs induced generation of reticulocytes but only
epoetin beta exacerbated pathological (pre-retinal) neovascularisation in comparison to controls (p,0.05). Only epoetin
delta induced a significant revascularisation response which enhanced normality of the vasculature (p,0.05). This was
associated with mobilisation of haematopoietic stem cells and their localisation to the retinal vasculature. Darbepoetin alfa
also increased the number of active microglia in the ischaemic retina relative to other ESAs (p,0.05). Darbepoetin alfa
induced retinal TNFa and VEGF mRNA expression which were up to 4 fold higher than with epoetin delta (p,0.001).
Conclusions: This study has implications for treatment of patients as there are clear differences in the angiogenic potential
of the different ESAs.
Citation: McVicar CM, Colhoun LM, Abrahams JL, Kitson CL, Hamilton R, et al. (2010) Differential Modulation of Angiogenesis by Erythropoiesis-Stimulating
Agents in a Mouse Model of Ischaemic Retinopathy. PLoS ONE 5(7): e11870. doi:10.1371/journal.pone.0011870
Editor: Neil A. Hotchin, University of Birmingham, United Kingdom
Received April 23, 2010; Accepted July 1, 2010; Published July 29, 2010
Copyright:  2010 McVicar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Part of this research was funded by a grant from Shire (Hampshire, UK) and Fight for Sight grant no. 1688. AWS and PR have received travel funding
from Shire. The funders agreed to the study design. They had no role in data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Part of this research was funded by a grant from Shire (Hampshire, UK). AWS and PR have received travel funding from Shire. This does
not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: a.stitt@qub.ac.uk
Introduction
Hypoxia-mediated secretion of erythropoietin (EPO) from the
kidney maintains erythrocyte mass through inhibition of apoptosis
in bone marrow precursors. EPO normally occurs at sustained
levels within the low picomolar range (1–7 pmol/L) and, while
levels can increase by more than 100-fold in severe hypoxia, a
negative feedback loop maintains plasma concentrations. As an
example of molecular versatility, EPO can also function in a
paracrine/autocrine manner to promote tissue survival during
ischaemic, toxic and traumatic insults [1]. EPO is expressed in
many organs where it can activate the EPO receptor (EPO-R),
sometimes in combination with the b-common receptor (bCR;
CD131) [2]. This tissue protective role is exemplified during
ischaemic brain injury in which hypoxia inducible factor (HIF-1a)
regulates EPO expression and serves to reduce infarct size [3].
Importantly, it has been demonstrated that administration of
exogenous human recombinant rHuEPO to pre-clinical models of
ischaemic injury can significantly reduce neurodegeneration by
preventing neuro-glial apoptosis [4].
The anti-apoptotic neuroprotective properties of EPO in
ischaemic tissues may occur concomitantly with angiogenesis
including promotion of revascularisation [5,6] and microvascular
remodelling [7]. The mechanism for EPO-mediated angiogenesis
is complex but includes phosphorylation of eNOS [8], [9] and
mobilisation of endothelial progenitor cells (EPCs) with their
recruitment to sites requiring vascular repair [10]. EPO-mediated
angiogenesis significantly improves wound repair [11], microvas-
cular re-modelling following myocardial infarction [12] and focal
cerebral ischaemia [13].
Exogenous EPO may also have important benefits in retinal
disease and its neuroprotective activity is shown by inhibition of
apoptosis following a variety of cellular insults [4,14,15,16,17]. In
an acute model of hyperoxia-induced retinal ischaemia, adminis-
tration of exogenous EPO prior to the hypoxic insult can protect
neurons, prevent vessel dropout and subsequently suppress the
stimulus for hypoxia-induced neovascularisation [18]. However,
the phase of disease during which EPO is introduced may alter the
outcome and, in the same model, EPO treatment whilst the retina
is experiencing hypoxia may enhance pathological, pre-retinal
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inhibition of Epo mRNA using interference RNA [19] or blocking
the action of EPO-R with soluble receptor [20] proved effective in
suppressing retinal neovascularisation. Although EPO therapy
may have neuroprotective benefits in certain eye diseases, such
treatment needs to be used judiciously.
Erythropoiesis stimulating agents (ESAs) are widely used
clinically. Their half lives and therefore their efficacy, are
dependent on the heavily sialylated N-linked glycans which
protect the protein from proteases and prevent rapid removal
from the serum by the asialoglycoprotein receptor. Epoetin delta
and epoetin beta each contain four N-linked glycans (Asn24I-
leThr; Asn38IleThr; Asn83SerSer) while epoetin alpha has been
engineered to contain two additional glycosylation sites (Asn57-
GlyThr; Asn115LysThr). The particular structures of the oligo-
saccharides are site specific and also depend on the particular
glycosylation processing pathways in each cell type. Epoetin delta
contains only human oligosaccharides which differ in some ways
from other ESAs expressed in CHO cells[21]. For example, CHO-
cell-derived epoetins display low levels of N-glycoylneuraminic
acid which is not present on sugars attached to Epoetin delta
because the human cell line lacks the necessary enzyme and
monosaccharide to carry out this step. Epoetin delta has
demonstrated efficacy for treatment of anaemia in patients with
chronic kidney disease whilst not inducing generation of anti-EPO
antibodies [22]. Beyond its erythrogenesis properties, epoetin delta
potential to induce tissue responses has not been closely evaluated
even though it has potential to interact quite differently with EPO-
receptors than other ESAs.
ESAs are mostly used to treat patients with anaemia but in
recent years there has been concern that recombinant EPOs have
potential to promote pathological angiogenesis in some clinical
settings. For patients with diabetic nephropathy or for those who
develop anaemia following chemotherapy, activation of EPO-Rs
with ESAs could promote accelerated retinopathy or tumour
vascularisation respectively. Therefore it is important to evaluate
the different ESAs used to treat anaemia and determine their
potential to promote angiogenic pathology [23,24]. In the current
study we have evaluated three commonly used ESAs and assessed
their angiogenic potential in vitro and in an established model of
ischaemia-induced proliferative retinopathy. We describe how the
angiogenic potential of the human cell-derived Epoetin Delta
differs from recombinant EPOs darbepoetin alfa, epoetin beta
derived from CHO cells and that these ESAs also have differential
impacts on ischaemic retina.
Methods
Normal-phase HPLC and N-glycans
Samples were reduced and alkylated before being set into SDS-
PAGE gel blocks, washed and digested with PNGase F, (Prozyme,
San Leandro, CA, USA) for 16 hours as previously described by
Royle et al [25] The eluted glycans were labelled with 2-AB using
the LudgerTag
TM 2-AB kit according to the manufactures
instructions. Normal-phase HPLC (NPHPLC) was performed
using a TSKgel Amide-80 5 mm (25064.6 mm) column, Waters
Alliance 2695 Separations Module with a Waters 2475 Multi
Wavelength Fluorescence Detector (lex =330 nm and lem =
420 nm) (Waters Corporation, Millford, MA, USA). A 180 min
gradient of 50 mM ammonium formate buffer, pH 4.4 and
acetonitrile was used for glycan separation as previously described
by Royle et al [25]. The systems were calibrated by running an
external standard of 2AB–dextran ladder (2AB–glucose homopol-
ymer, Ludger) alongside the sample runs.
ESAs and in vitro angiogenesis
The in vitro angiogenesis assay employed was a three
dimensional model of angiogenesis as previously described [26].
Human dermal microvascular cells (HDMEC) (Promocell, UK)
were suspended in an extracellular matrix gel (Matrigel, Becton
Dickinson, England). The HDMECs were cultured in endothelial
cell growth medium MV (Promocell, UK) and supplement growth
factors as recommended by Promocell.
HDMECs were plated in 30 ml circular spots of 50% Matrigel
diluted in medium until they formed endothelial tubular networks
around 48 hours post-seeding. Three different ESAs were then
added to a second layer of Matrigel superimposed on the primary
culture spots. The ESAs studied were epoetin delta (Dynepo),
darbepoetin alfa (Aranesp) and epoetin beta (Neorecormon) (0.1–
100 IU/ml). The calculation for equivalent doses of ESAs was
based on the fact that 200 IU of epoetin delta contains the same
peptide mass as 1 mg of darbepoetin alfa [27].
After a further 24 hours the number of endothelial sprouts that
had crossed the interface between the two layers were counted
around the entire circumference of each primary culture spot
using phase contrast microscopy. Angiogenic sprouting from the
primary to secondary gel layers was assessed for 9 spots/treatment
group. To confirm that autocrine VEGF secretion underlies the
angiogenic actions of EPO, the above experiment was repeated
with additional treatment groups for each ESA in which the ESA
was mixed with a VEGF neutralising antibody at 0.4 mg/ml
(Ranibizumab/Lucentis, Novartis, UK) VEGF (40 ng/ml) was
employed as a positive angiogenic control.
Oxygen-Induced Retinopathy Model
All experiments conformed to UK Home Office regulations
(project licence No. 2611) and were approved by Queen’s
University Belfast Ethical Review Committee for Animal Re-
search. Oxygen-induced retinopathy (OIR) was conducted in
C57/BL6 wild type mice according to the protocol of Smith et al.
[28]. In this model, 7-day-old (P7) mouse pups and their nursing
dams were exposed to 75% oxygen (humidified medical grade
oxygen controlled by a PROOX oxygen controller model 110;
Reming Bioinstruments Co. Redfield, NY) for 5 days causing vaso-
obliteration and cessation of development of the central retinal
capillary beds. On postnatal day 12 (P12) the mice were returned
to room air, after which there was acute retinal ischaemia in the
avascular regions of the central retina, followed by a potent pre-
retinal neovascular response between P15 and P21.
A total of 74 mice were divided into ten groups. Group 1
consisted of P12 controls (n=4) and was used to confirm that
consistent central vasobliteration occurred following hyperoxia
exposure. Groups 2, 3, & 4 received daily intraperitoneal (i.p.)
injections of low dose treatment of ESAs from P12-P16 inclusive
(n=7 pups/group). The low dose regime for group 2 was epoetin
delta (30 iu/Kg), while for group 3 it was equivalent dose of
darbepoetin alfa (0.15 mg/Kg) and for group 4 it was epoetin beta
(30 iu/Kg). For high-dose ESA treatments, group 5 received
epoetin delta (2500 iu/Kg) (n=14); group 6 received darbepoetin
alfa (12.5 mg/Kg) (n=7) and group 7 received epoetin beta
(2500 iu/Kg) (n=7).
For controls, group 8 (n=7) received i.p. formulation buffer
(sham control for epoetin delta), Group 9 (n=7) received PBS
(sham control for darbepoetin alfa and epoetin beta). The animals
from groups 2–9 were sacrificed at P17 with sodium pentobarbital.
In addition another group of mice (group 10) received the high
dose of epoetin delta 2500 IU/Kg after which they were sacrificed
at P23 (n=7).
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Haematocrit levels were quantified using the Sysmex SC9500
analyser (Japan). In addition, reticulocyte counts were conducted
since these cells are present in blood for ,48 hours before
developing into mature red blood cells. Reticulocytes represent an
appropriate evaluation for the acute experimental system em-
ployed. Blood was obtained from each pup by cardiac puncture
and placed in EDTA coated tubes. This was then mixed with
brilliant cresyl blue and incubated for 20 mins at 37uC. The blood
and stain was then smeared onto a glass slide and the number of
reticulocytes assessed using a 6100 oil objective lens.
Microvascular pathology
One eye from each pup (n=7 per treatment) was enucleated
and immediately fixed in 4% PFA. Retinal flat mounts were
stained with isolectin B4 (Sigma), co-stained with glial fibrillary
acidic protein (GFAP) (Dako) and with the corresponding
secondaries streptavidin Alexa Fluor 488 (Molecular Probes) and
Alexa Fluor 568 goat anti-rabbit IgG. DAPI (Sigma) was also
added to locate the nuclear layers of the retina. Stained retinas
were visualised and imaged using confocal microscopy (Eclipse
TE2000-U, Nikon, Japan). Avascular and pre-retinal neovascu-
larisation were quantified using Lucia Version 4.60 software as
previously described [29].
For some eyes, serial sections of the flat-mounts were
cryosectioned at 12 mm thickness (Leica, CM 1900 UV). Every
other section was stained with haematoxylin & eosin (H&E)
providing a total of 176612 mm serial sections. All odd number
sections were stained with H&E and all the even numbers were left
as fluorescent images. All fluorescent sections were imaged using a
confocal microscope. These serial sections were cut from the
peripheral retinal edge towards the optic nerve in the centre of the
retina. As each section transacted the full width of the quadrant
and was 12 mm in thickness the exact location of the section could
be mapped to the low magnification (x4) images of the flatmount
preparation. By examining each section in sequence and
correlating with the distance cut into the quadrant it was possible
to conclude exactly which region of the flat mount that was being
assessed in cross section.
Sca-1 (BD Pharmingen), a marker for haematopoietic stem cells
was co-labelled with isolectin B4 with the secondary antibody
Alexa Fluoro 568 donkey anti-goat (Invitrogen) in both P17 and
P23 retinas (n=7).
IBA1 (marker for microglia, Abcam) was co-stained with
isolectin B4 with the secondary antibody Alexa Fluoro 568 donkey
anti-goat (Invitrogen). Microglia were divided into four basic
morphological categories as described by Kettenmann et al. [30].
The number and the activation of the microglia were assessed in
the ischaemic area of the retina. Four Z-series images were
collected per specimen at640 using the Nikon Eclipse TE2000-U
Confocal Microscope C. Five specimens per treatment were
assessed.
Ultrastructural evaluation
Transmission electron microscopy (TEM) was used to evaluate
ultrastructural changes to the retina with high dose of epoetin delta
treatment. Flat-mounted retinae were post-fixed in fresh 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer at 4uC for a
minimum of 12 hrs and then further fixed in 1% osmium
tetroxide. Tissues were then processed through graded ethanol
and embedded in Spurr’s resin. Semi-thin sections were prepared,
stained with toluidine blue and retinal orientation evaluated in
accordance with the flat-mounts previously viewed using confocal
microscopy. Ultrathin sections were cut and floated onto 200 mesh
copper grids (Agar Scientific Ltd. UK), counter stained with uranyl
acetate and lead citrate. Sections were viewed on a Hitachi H-
7000 transmission electron microscope.
Bone marrow analysis
The femurs from each pup were removed and the marrow was
flushed from the femurs and stained either with: FITC-conjugated
anti-mouse Ly-6A/E (Sca-1) or the appropriate isotype IgG
control (all obtained from eBiosciences) for 45 mins at 4uC. The
cells were then washed in PBS and spun at 385 g. 10,000 cells
were assessed for each marker and the percentage of positive cells
was calculated using a Becton Dickinson FACSCalibur.
Quantitative RT-PCR (qPCR)
Freshly dissected mouse retinas from each HD-EPO-treated
experimental group (n=7 mice/group) were initially placed in
RNA Later (Sigma) and stored at 220uC. Total RNA was
subsequently extracted and purified (RNeasy Mini Kit; Qiagen,
Crawley, UK) with residual DNA removed by DNase I digestion
(Qiagen). The quantity and quality of RNA in each sample was
determined spectrophotometrically (Nanodrop Technologies,
UK). Equal amounts of RNA were reverse transcribed into cDNA
(Omniscript Reverse Transcription, Qiagen UK). Real-time
quantitative RT-PCR (qPCR) was performed using murine
sequence-specific primers for VEGF, TNF-alpha and IL-10.
ARP was used as a housekeeping expression control as previously
described [31]. Primer sequences are shown in table 1.
The PCR reaction mix contained 2 ml of cDNA, 0.3 mmol/L of
forward and reverse primer each, 10 ml of Quantitect SYBR
Green I mix (Qiagen) and 3.4 ml of RNAse free water making a
total reaction of 20 ml. The PCR conditions were as follows:
Denaturation, 95uC for 15 min; Amplification (45 cycles), 94uC
for 15 s, 61uC for 30 s, and 72uC for 15 s; For normalization of
expression data, a 109-bp fragment of the housekeeping ARP
mRNA was employed as previously described [31].
Results
Glycan profiling
The N-glycan pools were released from the three epoetins using
PNGase F and, after fluorescent labelling with 2-aminobenzamide,
were run on a HILIC HPLC column prior to detailed sequencing
(Figure 1). The profiles obtained on these high resolution columns
are a visual illustration of glycosylation differences between the
three ESAs This indicates significant changes in the levels of bi- tri-
and tetra-antennary glycans, in sialylation and in fucosylation. The
profile obtained for Epoetin delta has a predominant proportion of
sialylated core-fucosylated tetra-antennary glycans, reflected in the
higher GU values. A full N-glycan profiling for the different
Table 1. Primer sequences for murine sequence-specific
primers for housekeeping gene ARP, VEGF, TNF-alpha and IL-
10.
Forward Reverse
ARP 59CGACCTGGAAGTCCAACTAC39 59ATCTGCTGCATCTGCTTG39
VEGF 59TTACTGCTGTACCTCCACC39 59ACAGGACGGCTTGAAGATG39
TNF-a 59CCTCACACTCAGATCATCTTC39 59CGCTGGCTCAGCCAC TCC39
IL-10 59AGCAGCCTTGCAGAAAAGAG39 59TAGGAGCATGTGGCTCTGG39
doi:10.1371/journal.pone.0011870.t001
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results).
ESA-mediated angiogenesis in vitro
Initially the effect of epoetin delta (0.1–100 IU/ml) was
determined using the in vitro angiogenesis model in HDMECs as
described by Stitt et al. 2005[26]. Briefly, the in vitro assay was a
novel three-dimensional model of angiogenesis that used
HDMECs in an extracellular matrix gel. Next day, the second
layer of matigel was added with the ESA derivative. After a further
24 hours the number of endothelial sprouts that had crossed the
interface between the two layers were counted around the entire
circumference of each primary culture spot using phase contrast
microscopy.
This ESA induced no significant angiogenic response with doses
at ,20 IU/ml however at higher doses (.20 IU/ml) there was a
significant, stepwise increase in angiogenesis (p,0.001) (Figure 2).
This established that a dosing regime of 1, 20 and 100 IU/ml was
appropriate for subsequent experiments. VEGF (40 ng/ml) as an
appropriate positive control induced significant angiogenesis in
HDMEC cells (p,0.001) (Figure 3). The VEGF neutralising
antibody (Ranibizumab at 0.4 mg/ml) prevented VEGF bioactiv-
ity and significantly reduced VEGF-mediated angiogenesis to
negative control levels (Figure 3).
Epoetin delta induced angiogenesis in the HDMEC cells when
compared to controls (p,0.05) (Figure 3A). Darbepoetin alfa at an
equivalent dose was considerably more pro-angiogenic at the 1
and 20 IU/ml doses (p,0.001) although 100 IU/ml failed to
induce angiogenesis (Figure 3B). A biphasic angiogenic effect was
observed with Darbepoetin Alfa in HDMEC primary cells and
Human Microvascular Endothelial Cells (HMEC-1 cell line, data
not shown). Epoetin beta was similar to epoetin delta in that only
the 100 IU/ml dose was pro-angiogenic (Figure 3C). Ranibizu-
mab significantly attenuated the angiogenic effect of all three ESAs
(Figure 3A–C).
Erythrogenesis and acute ESA-treatment in neonatal
mice
The haematocrit in epoetin delta, darbepoetin alfa or epoetin
beta-treated mice showed no alteration when compared between
dosing levels and vehicle controls (data not shown). However, the
percentage of reticulocytes was also analysed as an early indicator
for erythrogenesis and these cells were significantly increased by
both low dose and high dose epoetin delta when compared to
control animals (p,0.05). Darbepoetin alfa and epoetin beta only
altered the percentage of reticulocytes with the high dose (HD)-
EPO regime (Figure 4).
ESA regulation of pre-retinal neovascularisation
Consistent with previous reports, OIR induced a temporal
pattern of central retina vascular insufficiency upon return to
room air at P12 which lead to a reproducible pre-retinal
neovascularisation observable on flat-mounts Figure 5 (B) and
verified in transverse sections as being on top of the internal
limiting membrane (ILM) (Figure 5 (C). Pre-retinal neovascular-
isation was quantified on flat-mounted retina at P17 (Figure 5B).
Epoetin delta or darbepoetin alfa treatment of pups with OIR
(treated daily P12–P16) did not influence pre-retinal neovascu-
larisation, irrespective of low or high-dose regime. By contrast
Figure 1. Glycan profiling. Normal phase HILIC profiles of N-linked glycans released from epoetins and labelled with 2-aminobemzamide. The
sections of the profiles where bi-, tri- and tetra-antennary glycans elute are indicated at the top of the figure. The elution positions are shown against
a scale of glucose oligomers used to calibrate the column.
doi:10.1371/journal.pone.0011870.g001
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ment of pre-retinal neovascularisation when compared to controls
(Figure 5D).
ESA treatment and retinal ischaemia and remodelling
ESA-treatment of OIR did not have a significant impact on
retinal ischaemia (as observed in Figure 6A–F) as quantified at P17
(Figure 6G). During the ischaemia analysis, it was observed that
the epoetin delta treatment caused a qualitative increase in lectin-
positive vasculature that was completely distinct from the
hyperfluorescent pre-retinal neovasculature. On flat-mount this
‘‘atypical’’ vasculature, was less fluorescent and the tubes were
considerably more dilated and less branched when compared to
the other retinal blood vessels (Figure 7A). From the flat-mount it
was impossible to determine if these atypical vessels were pre-
retinal in nature, but serial sections of the corresponding areas in
flat-mount demonstrated that these vessels were intra-retinal,
being localised to the nerve fibre layer and, especially, the outer
plexiform layer (Figure 7B & 7C). Electron microscopy revealed
that these atypical vessels were within the retina and had
immature basement membranes and sometimes lacked covering
by mural cells but they were often perfused, as evidenced by
erythrocyte profiles (Figure 7D & 7E). Calculating this intra-retinal
(atypical) vasculature on flatmounts with the corresponding
mapping from the serial sections, it was demonstrated that epoetin
beta or darbepoetin alfa treatments reduced the numbers of these
intra-retinal vessels in comparison to OIR controls (Figure 7F). By
contrast, epoetin delta significantly increased these vessels during
OIR (p,0.05) (Figure 7F).
In a parallel study, OIR mice were treated with epoetin delta or
vehicle control (Fig. 8A & 8B) and maintained up to P23 to
determine if the increase in intra-retinal vasculature observed at
P17 with epoetin delta helped the retinal microvascular recovery.
There was a significant reduction in the ischaemic area of the
epoetin delta-treated mice compared to controls (p,0.05)
(Figure 8C). Epoetin delta-treated mice also showed enhanced
areas of normal vasculature at P23 (p,0.05) (Figure 8D). The ratio
of normal vasculature:ischaemic retina was calculated for epoetin
delta-treated and control animals. The enhanced ‘‘normalisation’’
of the retina was also reflected in this ratio; 210:1 (epoetin-treated)
compared to 43:1 (formulation buffer treated). This equated to a
,5 fold enhancement of normal vasculature at P23 following
epoetin delta treatment.
Haematopoietic stem cells in marrow and retina
To determine if epoetin delta stimulated haematopoetic stem
cell (HSC) generation in bone marrow and if these cells appear in
the retinal microvasculature, the proportions of Sca-1
+ve cells
were assessed by flow cytometry in fresh marrow isolates and
by immunohistology in the retina. After 5 days treatment at P17
(P12–P16 Epoetin Delta injections), the number of SCA-1
positive (Sca-1
+ve) cells was significantly increased by epoetin
delta relative to the control (9.13% vs. 3.1%; p,0.001)
(Figure 9A). At P23 following continued treatment with epoetin
delta, there was still a significant difference when compared to
control (Figure 9B).
Sca-1 positive cells were abundant in the retina of epoetin delta-
treated OIR animals (Figure 9C–F). Sca-1
+ve cells were observed
in the blood column (Figure 9C) and they were particularly
apparent in the pre-retinal neovasculature (Figure 9D) and also
within and around the ‘‘intra-retinal’’ vessels inside the retinal
neuropile (Figure 9E, F).
Retinal microglia and cytokine expression
Microglia were assessed in the ischaemic retina (Figure 10A &B)
and were divided into two morphological groups defined as
ramified (inactive) (Figure 10C) or amoeboid (active) (Figure 10D)
[30]. The activation state of the microglia in the retina was
assessed in epoetin delta, darbepoetin alfa and epoetin beta treated
animals and in comparison to the control, there was no alteration
in the total number of microglia (Figure 10E). However,
darbepoetin alfa increased the number of active microglia relative
to the control (p,0.05) (Figure 10F). TNF-a and VEGF mRNA
was higher with darbepoetin alfa relative to the control
(Figure 11A,B) (n=6; p,0.001) and the anti-inflammatory
cytokine IL-10 was reduced with Epoetin Beta. Epoetin Delta
was higher than Darbepoetin Alfa and Epoetin Beta (Figure 11C)
(n=6; p,0.05).
Figure 2. The effect of Epoetin delta on angiogenesis in vitro. The effect of epoetin delta was determined using the in vitro angiogenesis
model in primary HDMEC cells. At doses .20 IU/ml there is a significant increase in angiogenesis (n=6). Doses ,20 IU/ml is not angiogenic. (Error
bars = Standard Error of the Mean ***p,0.001.
doi:10.1371/journal.pone.0011870.g002
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PLoS ONE | www.plosone.org 5 July 2010 | Volume 5 | Issue 7 | e11870Figure 3. VEGF dose response and prevention of EPO-induced angiogenesis by blockade of VEGF bioavailability. (A) In primary
HDMEC cells VEGF was used as a positive control and the anti-VEGF drug Lucentis reduced the angiogenic effect of Epoetin Delta (ED) at 100 IU/ml in
tubules grown from primary HDMEC cells. It had little effect on 1 and 20 IU/ml. (B) Darbepoetin Alfa (DA) was considerably more angiogenic than at
the 1 and 20 IU/ml doses (p,0.001) although 100 IU failed to induce angiogenesis. (C) Only Epoetin Beta (EB) at 100 IU/ml dose was pro-angiogenic.
(n=6) (Error bars = Standard Error of the Mean) *=p,0.05.
doi:10.1371/journal.pone.0011870.g003
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Alfa and Epoetin Beta
A summary of the effects of Epoetin Delta, Darbepoetin Alfa
and Epoetin Beta is located in Table 2.
Discussion
It is well established that recombinant EPO has pro-angiogenic
properties in vitro and in vivo [32,33]. In the current investigation, it
has been shown for the first time that the ESA, epoetin delta, also
possesses pro-angiogenic properties but that these differ apprecia-
bly from other ESAs used clinically. The observed EPO-mediated
angiogenic response is different between epoetin delta, darbepoe-
tin alfa and epoetin beta and is dose-dependent. This is reflected in
the distinct differences between the glycosylation profile of each
ESA studied. Unlike other ESAs studies, epoetin delta appears to
have significant tissue-protection properties for ischaemic retinop-
athy.
Recombinant EPO induces a dose-dependent increase in
endothelial cell proliferation with concentrations as low as 5 IU/
ml [34]. Epoetin delta also displays a similar dose response, but it
is interesting that there is a lack of angiogenic effect at ,20 IU/
ml and a significant induction at concentrations $20 IU/ml. We
have similarly shown that significant in vivo responses also
Figure 4. Percentage of reticulocytes as an early indicator for erythrogenesis. The percentage of reticulocytes were analysed as an early
indicator for erythrogenesis and these cells were significantly increased by low dose of Epoetin Delta and high dose of Epoetin Delta (A) when
compared to control animals (n=6)) (*p,0.05). Darbepoetin Alfa (B) (***p,0.001) and Epoetin Beta (C) (*p,0.05) only altered the percentage of
reticulocytes with the high dose of EPO. (Error bars = Standard Error of the Mean).
doi:10.1371/journal.pone.0011870.g004
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that low dose EPO is sufficient for erythropoietic effects while
higher doses are required for tissue protective effects and Brines
and Cerami have suggested that this response may be linked to
differential affinity of EPO-R and BCR for EPO [35]The high-
affinity of EPO-R establishes erythropoiesis at low concentration
ranges while the low-affinity of BCR typically requires higher
concentrations of EPO (.500 IU/Kg) to provoke tissue
protection [35]. We have demonstrated that epoetin delta in
particular induced erythropoiesis at low and high doses but
angiogenesis was only induced by higher doses. EPO-R is
expressed by microvascular endothelial cells [34] and ligand
binding is likely to evoke signalling through the MAPK and
PI3K/Akt pathways [36] [37]. In these cells there is also possible
involvement of the bCR
[2] although this was not evaluated as
part of this study.
In the in vitro angiogenesis system used in the present study, it
was apparent that darbepoetin alfa was more pro-angiogenic at
low concentrations than the two epoetins. In the in vitro
angiogenesis system used in the present study, it was apparent
that darbepoetin alfa was more pro-angiogenic at low concentra-
tions than the two epoetins. Such a biphasic angiogenic effect has
been previously speculated for Darbepoetin Alfa [20] similar to
what occurs with VEGF. This could help explain what we have
observed with Darbepoetin Alfa.
It was also apparent that VEGF neutralisation significantly
reduced EPO-induced angiogenesis, indicating that this re-
sponse is mediated, at least in part, by endothelial-derived
VEGF. It has been demonstrated that recombinant EPO can
induce VEGF expression in neural progenitor cells which, in
turn, can induce an angiogenic response [37]; however, in the
endothelial cell monoculture, it would appear that EPO can
Figure 5. Epoetin delta and Darbepoetin Alfa does not alter pre-retinal neovascularisation in the OIR model. Representative flat-
mount of the retina following OIR in a control sample. The typical ischaemic (isch) area of the retina is traced while the normal vasculature (norm) and
neovascularisation (neo) is also represented (A). A typical cluster of vascular structures represented as ‘‘neovasculature’’ on a flat-mounted retina (B).
When this flat mount is sectioned it shows that these vessels are on top of the retina (C). Epoetin Delta (ED), Darbepoetin Alfa (DA) or Epoetin Beta
(EB) treatment of pups with OIR from P12–P17 at low or high dose illustrated that Epoetin Delta and Darbepoetin Alfa did not influence pre-retinal
neovascularisation, irrespective of dosing regime, however there was an increase in pre-retinal neovascularisation at both low and high doses of
Epoetin Beta (D) (Error bars = Standard Error of the Mean). This data has implications for usage of these Erythropoietic stimulating agents (ESAs) in
anaemic patients who could have enhanced risk of tumour neovascularization, rheumatoid arthritis and proliferative retinopathy. From this study our
data shows that only Epoetin Beta increased the pathological neovascularization. ESAs induce angiogenesis in ischaemic retinopathy but vary in
terms of promoting normal retinal perfusion and activation of ischaemic-linked pro-inflammatory responses by the retina.
doi:10.1371/journal.pone.0011870.g005
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although the precise signalling mechanisms involved remain
uncertain. VEGF is a recognised driver for retinal angiogenesis
and such a response, if it occurs in vivo, would have important
implications for disease-related elevations in EPO and for VEGF
neutralisation therapy. This is supported by a recent report
in a model of myocardial infarction in which EPO increased
VEGF protein expression and improved revascularisation of the
ischaemic myocardium; administration of VEGF-neutralizing
antibodies prevented this EPO-mediated enhancement of
cardiac revascularisation [38].
Haematocrit levels were quantified in this study but there was
no alteration in the blood of the mice which were treated for 5
days (P12–16) and then sacrificed at P17. It takes 10 days to alter
the haemocrit level. Therefore, in this study the percentage of
reticulocytes were analysed as an early indicator for erythrogenesis
and these cells were increased by both low and high dose of
Epoetin delta and only the high dose of Darbepoetin alfa and
Epoetin beta increased the reticulocytes. These findings suggest
that the human cell derived Epoetin delta is more effective at
increasing the reticulocytes in mice. This should be tested in
humans also as Epoetin delta could be a more effective treatment.
An important objective for the current study was to determine
the effects of three ESAs on the risk of pre-retinal neovascular-
isation which is a major sight-threatening end-point of many
ischaemic retinopathies. We demonstrated that Epoetin delta and
Darbepoetin alfa produced no significant exacerbation of pre-
retinal neovascularisation, even at the highest dose. Epoetin beta
on the other hand, did show an increase in pre-retinal
neovascularisation compared to controls. The differences between
Figure 6. Representative flat-mounts of the retinas following OIR treated with the three ESAs. Flat-mounted retina shows the ischaemic
areas highlighted following treatment with low dose of epoetin delta (ED) (A) darbepoetin alfa (DA) (B) epoetin beta (EB) (C) and high dose of epoetin
delta (D) darbepoetin alfa (E) and epoetin beta (F). Epoetin Delta, Darbepoetin Alfa or Epoetin Beta treatment of pups with OIR from P12–P17 at low
or high dose had no significant influence on the extent of retinal ischaemia (avascular area) (G).
doi:10.1371/journal.pone.0011870.g006
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retinal neovascularisation is also demonstrated by a previous study
in which OIR mice were treated with epoetin alfa (at a dose of
5,000 IU/Kg) at comparable time-points to those observed in the
current study and showed enhanced pathological neovascularisa-
tion [18]. The lack of pathological neovascularisation in treatment
with epoetin delta is therefore unexpected, especially since it has
been demonstrated that raised endogenous EPO levels are
associated with proliferative diabetic retinopathy [20,39]. Also in
the OIR model, Watanabe et al have suggested that inhibition of
EPO receptor signalling using a soluble receptor peptide delivered
as an intravitreal injection prevented pre-retinal neovascularisa-
tion [20]. Therefore the differences in angiogenic potential
observed between the recombinant EPOs Darbepoetin Alfa and
Epoetin beta and the human cell derived Epoetin Delta in the
present study may reflect a ligand-mediated modulation of the Epo
receptor with differential downstream signalling outcomes and
suggests that the potential risks of administering an ESA to patients
with proliferative retinopathies [18,20] may be avoided by careful
choice of the EPO mimetic.
An important outcome of the current investigation is that
treatment with epoetin delta significantly enhances intra-retinal
neovascularisation, a response that was distinctive from other ESA
treatments. The intra-retinal new vessels observed in epoetin delta-
treated mice were spatially and morphologically distinct from the
pathological vessels above the internal limiting membrane of the
retina. It is pertinent to note that intraretinal neovascularisation is
not necessarily a beneficial response and in some cases
Figure 7. Epoetin delta modulates intra-retinal neovascularisation. The retina in Epoetin delta-treated mice often demonstrated lectin-
stained ‘‘atypical vessels’’ (A). This is a dismounted flatmount imaged immediately prior to cryobedding. A representative of the serial sections of the
flat-mounts is illustrated in Fig. (B). The area within the white box of Fig. 7B is more clearly illustrated in Fig. 7B Here it is clear that the ‘‘atypical
vessels’’ are located inside the retina with lectin stained green and GFAP red (C). Using electron microscopy it is evident that the neovascular tissue
and glial cells were on both sides of the internal limiting membrane (green arrows) (D). The pre-retinal vessels often had pericyte covering (P) and
multiple glial associations (G) although both intra- and preretinal vessels had well-formed lumens (L). In the middle of the ischaemic regions there
were exclusively intra-retinal vessels in the nerve fibre layer and sometimes between the Inner nuclear layer (INL) and outer nuclear layer (ONL) that
were perfused with red blood cells in the lumen (RBC) (E). Epoetin delta treatment at high dose significantly increased ‘‘atypical’’, intra-retinal
vascularisation in OIR (*p,0.05) (F). Low dose displayed no difference in the ‘‘atypical’’, intra-retinal vascularisation of the entire retina. Darbepoetin
Alfa and Epoetin Beta reduced the intra-retinal vascularisation of the retina (p,0.05) (n=7). (Error bars = Standard Error of the Mean).
doi:10.1371/journal.pone.0011870.g007
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pathology are linked to retinopathies. However, the intra-retinal
vessels observed following epoetin delta treatment appeared
morphologically dissimilar to RAP described for example in the
retina of Vldlr-/- mice [40] The intra-retinal capillaries described
in the current study were newly formed, reflected by their electron-
lucent immature basement membranes and incomplete coverage
of pericytes. They were also perfused as indicated by the presence
of erythrocytes in their lumena. Extended epoetin delta treatment
to P23 demonstrated an absence of these intra-retinal vessels and
the retinal vasculature from treated mice appeared more normal.
Therefore such vessels could to contribute to re-vascularisation of
the ischaemic central retina during OIR and promote significant
normalization of the vasculature when compared to controls.
Intra-retinal neovascularisation can often be a highly beneficial
phenomenon in OIR because it can reduce retinal hypoxia and
thereby reduce the stimulus for pathological neovascularisation
[29,41].
It has been previously demonstrated that treating mice with
recombinant EPO in the early stages of OIR (P6–12) prevents the
vaso-obliterative stages of this pathology, possibly through
mobilization of endothelial progenitor cells [18]. Janmaat et al.
also treated mice with epoetin delta and found comparable
numbers of circulating HSCs [42]. This phenomenon is also
reflected in our study, in which epoetin delta treatment leads to an
increase in HSCs, their mobilization in the bone marrow and the
appearance of early markers for endothelial progenitors in the
retinal neovasculature. EPO is a potent mobilization factor for
HSCs [43,44] and they can be harnessed to re-vascularise the
ischaemic retina in OIR [40]. A recent study has indicated that
EPO can improve cardiac revascularization by mobilization of
EPCs and their participation in microvascular regeneration, but
only when ischaemia is present [38]. A similar phenomenon could
be at play in the retina and EPCs appear to be critical for the
observed re-vascularisation of non-perfused retina, although this
requires further investigation.
Figure 8. Epoetin delta enhances vascular recovery following OIR. Figs. 8 (A and B) illustrate the recovery of the vasculature in the retina and
the ischaemic regions at P23 following OIR for formulation buffer treated mice and those which were treated with high dose of epoetin delta. Upon
quantification the ischaemic area is decreased in epoetin delta treated mice relative to the formulation buffer treated animals (C) (*p,0.05) (n=6).
Inversely related to ischaemia, the area of normal vasculature is increased at P23 following epoetin delta treatment (D) (*p,0.05) (n=6) (Error bars =
Standard Error of the Mean).
doi:10.1371/journal.pone.0011870.g008
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central nervous system and while they may maintain tissue
homeostasis they are also involve in inflammation and neurovas-
cular dysfunction. Retinal microglia are directly involved in
cytokine expression in response to ischaemia and may regulate
angiogenesis in the neuropile [40,45]. In this study, a higher
proportion of active microglia was observed with Darbepoetin alfa
compared to Epoetin delta and Epoetin beta and this may be
associated with the higher expression levels of VEGF and TNF-
alpha mRNA in retina relative to Epoetin beta or Epoetin delta. In
addition, in the current investigation, epoetin delta increased the
intra-retinal vasculature although it did not alter the number of
microglia within the retina nor induce appreciable upregulation of
TNF-alpha or VEGF. There was a higher level of epoetin delta
induced expression of the anti-inflammatory cytokine IL-10
compared to darbepoetin alfa and epoetin beta. IL-10 has been
previously shown to suppress pathological retinal angiogenesis [46]
and reduce retinal inflammation [47] in murine models and it is
possible that epoetin delta could augment expression of this
cytokine in the retina, as has been shown for other EPO-treatment
of other ischaemic tissues [48].
There is no direct clinical evidence that systemic EPO can
promote accelerative retinopathy in people with diabetic renal
failure. However, Watanabe et al., 2005 [20]suggests that the level
of EPO in the vitreous fluid of patients with proliferative diabetic
retinopathy is higher than the level in diabetic patients. Indeed,
EPO was more strongly associated with proliferative diabetic
retinopathy than was VEGF. However, there was no significant
correlation observed between the vitreous and plasma levels of EPO
so increased levels in the vitreous could be due to increased local
Figure 9. Epoetin delta stimulates haematopoetic stem cells in bone marrow and infiltration into the retinal vasculature. Sca-1 is a
marker for haematopoetic stem cells (HSCs) and this was significantly enhanced in the marrow of mice treated with epoetin delta, both at P17 (A) and
also P23 (B). (n=5/group) ***p,0.001 (Error bars = Standard Error of the Mean). Sca-1 immunoreactivity in retinal flat-mounts demonstrated that this
HSC marker was present in cells localised to intra (C) and pre-retinal blood vessels (D). Assessment of the retinal vasculature penetrating the
ischaemia retina at P23 demonstrated that these vessels contained many Sca-1 positive cells (E). As with P17, these cells were also in clusters of pre-
retinal neovessels at P23 (F).
doi:10.1371/journal.pone.0011870.g009
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three intravitreal injections of erythropoietin therapy for patients
with chronic and progressive diabetic macular edema. They have
stated the case study shows a short term positive response to EPO
where their visual acuity was improvedfor the patients assessed with
chronic diabeticmacular edema.Thepatients were only assessed up
to 18 weeks after the first injection and there was no mention of the
EPO treatment promoting accelerative retinopathy but the patients
were only assessed for 18 weeks. Lappin et al., 2007 [24]has stated
that additional research is needed urgently to determine the effects
of ESAs on risk thrombosis, rate of tumour growth and
neovascularization in vivo and in vitro. The DAHANCA report
2007[50] has stated that the administration of Darbepoetin Alfa
results in greater mortality than with placebo while patients who
Figure 10. Alterations in activity of microglia in ischaemic area of the retinas of P17 ESA treated mice. Microglia were assessed in the
ischaemic area of the retina (A and B) and divided into two groups – ramified (C) and ameboid (D). The activity of the microglia in the retina was
assessed in the high dose of epoetin delta, darbepoetin alfa and epoetin beta. (E) There was no overall alteration in the number of microglia with
Epoetin Delta (ED), Darbepoetin Alfa (DA) or Epoetin Beta (EB) administered relative to the control (n=5 retinas assessed, four ischaemic areas per
retina). In (F) The high dose of Darbepoetin Alfa increased the number of ramified microglia relative to the control (p,.05) (Error bars = Standard
Error of the Mean).
doi:10.1371/journal.pone.0011870.g010
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tumours (Henke et al., (2003) [51].
In summary, this investigation has demonstrated that ESAs
have distinct and significant impact on angiogenesis in vitro and in
vivo. Such apparently enigmatic responses are closely linked to
dosing regimen and stage of disease and even the same
recombinant EPO can induce remarkably different responses
when delivered prior to or at the onset of hypoxia [18]. Such
Figure 11. The concentration of EPO administered i.p. alters growth factors and cytokines mRNA in the retina. (A & B) TNF-alpha and
VEGF was higher with darbepoetin alfa relative to the control. (n=6***p,0.001). (C) IL-10 was reduced with EPO treatment only with Epoetin Beta.
(n=6) (*p,0.05;) (Error bars = Standard Error of the Mean).
doi:10.1371/journal.pone.0011870.g011
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PLoS ONE | www.plosone.org 14 July 2010 | Volume 5 | Issue 7 | e11870differences may also reflect distinct biological properties derived
from different post-translational modifications such as glycosyla-
tion which are governed by the manufacturing process of these
ESAs. The disparity between the human cell derived epoetin delta
and the recombinant EPOs should be carefully considered when
prescribing ESAs in patients who are at risk for ischaemic
retinopathy.
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